Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.7 CHF | +1.66% |
|
+1.66% | +12.46% |
20/06 | Basilea Pharmaceutica to Sell Brain Cancer Drug Candidate to US-based Nonprofit | MT |
20/06 | Basilea partners oncology drug candidate lisavanbulin with Glioblastoma Foundation | DJ |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.46% | 53Cr | |
+18.97% | 4.53TCr | |
+41.98% | 4.04TCr | |
-10.06% | 3.79TCr | |
+31.15% | 3.18TCr | |
-7.79% | 2.77TCr | |
+13.32% | 2.65TCr | |
+43.05% | 1.4TCr | |
+31.28% | 1.24TCr | |
-7.41% | 1.13TCr |
- Stock Market
- Equities
- BSLN Stock
- News Basilea Pharmaceutica AG
- Transcript : Basilea Pharmaceutica AG Presents at JP Morgan 37th Annual Healthcare conference, Jan-10-2019 08